A 2023 observational study noted that patients receiving both therapies experienced greater reductions in body mass index compared to single-agent therapy, though the sample size was modest and long-term safety data remain incomplete
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
7 Still, Le, who is also a general surgery registrar at Royal Melbourne Hospital, says, I think it is too early to say this is a robust, durable, and generalizable effect given the high heterogeneity of underlying studies. He notes a need for more rigorous randomized controlled trials with longer follow-up times to better characterize the impact of these medications on weight and OSA together, as well as gain a better understanding of effect size, optimal doses, side effects, interactions with other medications, and impacts on other comorbidities
10.1016/j.psyneuen.2019.02.006 71 VallofD.KalafateliA
